>> Ph3 was mainly USA, Central and Western Europe, unlike your quoted "distorted" results of Phase 2.
That's probably why there was no separation between the two arms at all in ph3 trials because patient population for ph3 significantly differ from ph2 trials, resulting futility at 1st interim for both ph3 trials. That's the ironic part after trying to do the RIGHT things for ph3 trials after miserable ph2 trials.
>> and the Bavi arm performed as expected, that is close to revised Ph 2.
No, it isn't. "The interim analysis showed that the bavituximab combination group is performing as expected according to the original trial assumptions in terms of overall survival". There was big qualifier there "original trial assumptions in terms of overall survival". Based on SUNRISE sample size, and numerous previous trials in 2nd line NSCLC, it is quite easy to figure out what those assumptions were. If you don't believe it, oh well.
Market Data 
Markets 
AI
